Imagion Biosystems is now a publicly traded company after completing a heavily supported A$12 million initial public offering (IPO) on the Australian Securities Exchange. Imagion issued 60 million new shares as part of the IPO at A$0.20 per share, valuing the company at A$43 million upon listing.
The company’s shares trade under the symbol IBX on the Australian Securities Exchange. Download the official announcement.
Corporate Update – IND for MagSense® HER2 Phase 2 Study Immediate Priority
November 14, 2024
Corporate Updates: $3M fundraising led by CPS Capital to be completed in early December Filing of IND for MagSense® HER2 Phase 2 Study Immediate Priority